CRISPR Therapeutics AG (CRSP) Receivables (2015 - 2024)

CRISPR Therapeutics AG has disclosed Receivables across 10 years of filings, most recently posting $27.1 million for Q4 2024.

• Receivables for Q4 2024 came in at $27.1 million, down 86.88% year-over-year; the trailing twelve-month figure through Dec 2024 was $27.1 million (down 86.88% YoY), and the FY2024 annual result was $27.1 million, down 86.88% from the prior year.
• Receivables came in at $27.1 million for Q4 2024 at CRISPR Therapeutics AG, down from $206.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $206.5 million in Q4 2023 to a low of $49000.0 in Q3 2022.
• The 5-year median for Receivables is $10.8 million (2020), against an average of $29.0 million.
• Across the five-year window, Receivables slumped 99.7% in 2021 and jumped 105960.61% in 2023, its largest moves.
• CRISPR Therapeutics AG's Receivables stood at $10.8 million in 2020, then decreased by 19.73% to $8.7 million in 2021, then advanced by 28.66% to $11.2 million in 2022, then jumped by 1743.75% to $206.5 million in 2023, then tumbled by 86.88% to $27.1 million in 2024.
• The last three Receivables figures came in at $27.1 million (Q4 2024), $206.5 million (Q4 2023), and $70.0 million (Q2 2023), per Business Quant data.